Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

被引：31

作者：

Plesner, Torben ^{[1
]}

Arkenau, Hendrik-Tobias ^{[2
]}

Gimsing, Peter ^{[3
]}

Krejcik, Jakub ^{[1
]}

Lemech, Charlotte ^{[2
]}

Minnema, Monique C. ^{[4
]}

Lassen, Ulrik ^{[3
]}

Laubach, Jacob P. ^{[5
]}

Palumbo, Antonio ^{[6
]}

Lisby, Steen ^{[7
]}

Basse, Linda ^{[7
]}

Wang, Jianping ^{[8
]}

Sasser, A. Kate ^{[8
]}

Guckert, Mary E. ^{[8
]}

Yeh, Howard ^{[9
]}

Ahmadi, Tahamtan ^{[8
]}

Lokhorst, Henk M. ^{[10
]}

Richardson, Paul G. ^{[11
,12
]}

机构：

[1] Vejle Hosp, Vejle, Denmark

[2] Sarah Cannon Res Inst, London, England

[3] Univ Copenhagen, Rigshosp, Dept Haematol, DK-2100 Copenhagen, Denmark

[4] UMC Utrecht Canc Ctr, Dept Hematol, Utrecht, Netherlands

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Univ Turin, Turin, Italy

[7] Genmab AS, Copenhagen, Denmark

[8] Janssen Res & Dev LLC, Spring House, PA USA

[9] Janssen Res & Dev LLC, Raritan, NJ USA

[10] UMC Utrecht, Hematol, Utrecht, Netherlands

[11] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA

[12] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.507.507

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca Marianatal
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, James D.
Perrot, Aurore
Laubach, Jacob
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan
Richardson, Paul G.
BLOOD, 2017, 130
[2] Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, Jamie
Perrot, Aurore
Laubach, Jacob P.
Krejcik, Jakub
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan M.
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : E35 - E39
[3] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Palumbo, Antonio
Lisby, Steen
Basse, Linda
Wang, Jianping
Sasser, A. Kate
Guckert, Mary E.
de Boer, Carla
Khokhar, Nushmia Z.
Yeh, Howard
Clemens, Pamela L.
Ahmadi, Tahamtan
Lokhorst, Henk M.
Richardson, Paul G.
BLOOD, 2016, 128 (14) : 1821 - 1828
[4] Addition of daratumumab to the combination of lenalidomide and dexamethasone in relapsed or refractory myeloma
Stocker, Nicolas
HEMATOLOGIE, 2019, 25 (01): : 10 - 11
[5] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
BLOOD, 2014, 124 (21)
[6] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 104 - 104
[7] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos, Meletios A.
San-Miguel, Jesus
Belch, Andrew
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Casneuf, Tineke
Chiu, Christopher
Soong, David
Sasser, A. Kate
Khokhar, Nushmia Z.
Avet-Loiseau, Herve
Usmani, Saad Z.
HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
[8] Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Wong, Xin Yi
Chng, Wee Joo
Aziz, Mohamed Ismail Abdul
Ng, Kwong
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 207 - 215
[9] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte Rose
Minnema, Monique
Lassen, Ulrik Niels
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary
Brun, Nikolai C.
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
Siegel, D. S.
Weber, D. M.
Mitsiades, C. S.
Dimopoulos, M. A.
Harousseau, J. L.
Rizvi, S.
Howe, J.
Reiser, D.
Anderson, K. C.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →